New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
08:12 EDTHSP, DANOYHospira to obtain financial benefits from possible Danone deal, says Wells Fargo
After multiple media sources reported that Hospira (HSP) is in talks to buy Danone's (DANOY) medical nutrition business in a potential tax inversion deal, Wells Fargo estimates that the deal could be 9%-12% accretive to Hospira's EPS in 2015-2017 if it's an all-stock deal and 20%-22% accretive if it's a 50%/50% cash and stock deal. The firm The firm estimates that Hospira's tax bill would be cut to 21% in 2015 and 19% afterwards, from its current forecast of 24%-26% during those years. The firm thinks the strategic rationale for the deal from Hospira's perspective, however, is less clear. It keeps a Market Perform rating on the stock.
News For HSP;DANOY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
16:20 EDTDANOYOn The Fly: Closing Wrap
Subscribe for More Information
12:37 EDTDANOYOn The Fly: Midday Wrap
Subscribe for More Information
10:14 EDTDANOYMead Johnson volatility elevated, Danone not carrying out a review for takeover
Subscribe for More Information
09:22 EDTDANOYOn The Fly: Pre-market Movers
Subscribe for More Information
08:04 EDTHSPGerman fund pressured to sell Mylan stake over drug used in executions, FT says
Subscribe for More Information
06:00 EDTDANOYDanone acquisition of Mead would not be well received, says Bernstein
Subscribe for More Information
October 19, 2014
14:18 EDTDANOY, HSPFresenius, others explore bid for Danone medical nutrition unit, Reuters says
Subscribe for More Information
13:21 EDTDANOYDanone says not carrying out review on Mead Johnson takeover, Reuters says
In response to reports on Friday that French food company Danone (DANOY) was pursuing a takeover of pediatric nutrition company Mead Johnson (MJN), Danone made a statement on Sunday saying that it was not carrying out a review of a Mead Johnson takeover, says Reuters. Reference Link
October 17, 2014
16:17 EDTDANOYOn The Fly: Closing Wrap
Subscribe for More Information
12:57 EDTDANOYDanone to pursue takeover of Mead Johnson, sources say, Reuters reports
Subscribe for More Information
12:36 EDTDANOYDanone will pursue Mead Johnson takeover, sources say, Reuters reports
Subscribe for More Information
October 15, 2014
08:28 EDTDANOYDanone reports Q3 like-for-like sales up 6.9% to EU 5.42B
Danone confirmed its 2014 targets of sale growth between 4.5%-5.5%, trading operating margin stable within a range of down 20bps and up 20bps and free cash-flow of around EU 1.5B excluding exceptional items.
October 14, 2014
11:23 EDTHSPBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 8, 2014
13:00 EDTHSPHospira recalling one lot of Vancomycin Hydrochloride
The FDA announced that Hospira is initiating a voluntary nationwide user-level recall of one lot of Vancomycin Hydrochloride. The action is because the product may have experienced temperature excursions during shipment to a customer and then was further distributed by the customer, the agency said. It added that there have been no adverse events or complaints reported for the affected lot. Hospira is "undertaking the recall out of an abundance of caution," the FDA said.
October 7, 2014
07:06 EDTHSPOmeros, Hospira enter into commercial suply agreement for Omidria
Omeros Corporation (OMER) said in a filing that on October 3, it, Hospira S.p.A. and Hospira Worldwide, Inc. (HSP) entered into a Commercial Supply Agreement, pursuant to which Hospira will act as a non-exclusive supplier of Omeros’ product Omidria for commercial sale in the United States and the European Union. Pursuant to the Supply Agreement, Hospira has agreed to manufacture and supply, and Omeros has agreed to purchase, a minimum percentage of Omeros’ requirements of Omidria for commercial sales and clinical supplies for the development of additional therapeutic indications in the United States. In addition, upon receipt of marketing approval in the EU, Hospira has agreed to manufacture and supply a portion of Omeros’ requirements of Omidria in the EU in an amount to be mutually agreed by the parties within four months of marketing approval in Europe, with there being no minimum purchase and supply requirement in the EU if the parties do not reach agreement during such time period and the agreement is not amended thereafter. The Supply Agreement obligates Omeros to provide to Hospira a rolling, non-binding long-term forecast of Omeros’ estimated required quantities of Omidria. The Supply Agreement has an initial term of five years from the date of first commercial sale of Omidria in any country in the Territory. Upon termination of the Supply Agreement, except in the case of termination for an uncured breach by Hospira, Omeros will be required to purchase all of Hospira’s inventory of Omidria and, if applicable, work in progress and reimburse Hospira for all supplies purchased or ordered based on firm purchase orders or Omeros’ estimates of its requirements of Omidria.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use